| Literature DB >> 30112678 |
Masahiko Kubo1, Hiroshi Wada1, Hidetoshi Eguchi2, Kunihito Gotoh1, Yoshifumi Iwagami1, Daisaku Yamada1, Hirofumi Akita1, Tadafumi Asaoka1, Takehiro Noda1, Shogo Kobayashi1, Masahisa Nakamura3, Yusuke Ono3, Keigo Osuga3, Eigoro Yamanouchi4, Yuichiro Doki1, Masaki Mori1.
Abstract
BACKGROUND: Magnetic compression anastomosis (MCA) is a minimally invasive method of anastomosis that does not involve a surgical procedure in patients with stricture, obstruction, or dehiscence of anastomosis after surgery. We experienced a case of complete dehiscence of bilioenteric anastomosis that was successfully treated by MCA. CASEEntities:
Keywords: Complete dehiscence of bilioenteric anastomosis; Living-donor liver transplantation; Magnetic compression anastomosis
Year: 2018 PMID: 30112678 PMCID: PMC6093822 DOI: 10.1186/s40792-018-0504-6
Source DB: PubMed Journal: Surg Case Rep ISSN: 2198-7793
Fig. 1In redo surgery, biliary drainage tubes that were inserted from the stumps of the RAD and PRD were exteriorized through the abdominal free space and abdominal wall. The jejunum was simply placed and fixed near the RAD and RPD for future anastomosis by MCA. RAD right anterior duct, RPD right posterior duct
Fig. 2a We checked that the stumps of the RAD (black arrow) and RPD (white arrow) were near the bowel for MCA by contrast radiography. We placed PTCD tubes in the RAD (black arrowhead) and RPD (white arrowhead). b MCA for the RAD was performed. The magnet (black arrow) was introduced into the bowel near the RAD by double-balloon endoscopy, and another magnet (white arrow) was inserted through PTCD of the RAD. c We confirmed the outflow of the contrast agent into the bowel (black arrowhead) via the PTCD tube placed in the RAD (white arrowhead). The bilioenteric fistula of the RAD was completed 21 days after MCA. MCA magnetic compression anastomosis, RAD right anterior duct, RPD right posterior duct
Fig. 3a We checked the stumps of the RPD (white arrow) by 3D reconstruction of CT image. b MCA for the RPD was performed by the same procedure as that for the RAD. c The bilioenteric fistula of the RPD was completed 47 days after MCA. The PTCD tube was introduced into the bowel to maintain the fistula through re-anastomosis of RPD (white arrow). MCA magnetic compression anastomosis, RAD right anterior duct, RPD right posterior duct
Characteristics and outcomes of patients who underwent magnetic compression anastomosis for biliary complications after living-donor liver transplantation
| Years | Author | No. | Age (years) | Sex | Disease | Reconstruction | Biliary complication | Intervention | Distance (mm) | Duration from LDLT (months) | Period until removal of magnet (days) | Duration of internal catheter (weeks) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2005 | Muraoka et al. [ | 1 | 1 | F | FH | R-Y | Stricture | CJS | N/A | 6 | 12 | 8 | Success |
| 2 | 57 | M | LC | R-Y | Stricture | CJS | N/A | 7 | 12 | 8 | Success | ||
| 2005 | Okajima et al. [ | 3 | 44 | F | FH | D-D | Obstruction | CCS | N/A | 12 | 42 | 12 | Success |
| 2008 | Akita et al. [ | 4 | 34 | F | N/A | D-D | Obstruction | CCS | 5 | 0 | 21 | 0 | Success |
| 2008 | Mita et al. [ | 5 | 0.5 | F | FH | R-Y | Obstruction | CJS | N/A | 1.5 | 12 | N/A | Success |
| 6 | 59 | F | LC | R-Y | Obstruction | CJS | N/A | 5 | 25 | N/A | Success | ||
| 2009 | Matsuno et al. [ | 7 | 53 | M | N/A | D-D | Stricture | CCS | 3 | N/A | 10 | 4.3 | Success |
| 2010 | Marubashi et al. [ | 8 | 53 | M | LC (HBV) | D-D | Dehiscence | CCS | N/A | 6 | 63 | 72 | Success |
| 2010 | Itoi et al. [ | 9 | 60 | M | N/A | D-D | Obstruction | CCS | N/A | 18 | 9 | 24 | Success |
| 2011 | Kawakubo et al. [ | 10 | 56 | M | LC (HCV) | R-Y | Obstruction | CJS | N/A | 9 | 23 | 56 | Success |
| 2011 | Jang et al. [ | 11 | 63 | F | LC (HBV) | D-D | Stricture | CCS | N/A | 71 | 42 | 83 | Success |
| 12 | 49 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 6 | 26 | 70 | Success | ||
| 13 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 55 | 18 | 49 | Success | ||
| 14 | 64 | F | LC (HBV) | D-D | Stricture | CCS | N/A | 71 | 71 | 14 | Success | ||
| 15 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 15 | 102 | 26.7 | Success | ||
| 16 | 48 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 13 | 102 | 25.7 | Success | ||
| 17 | 63 | F | Liver failure (drug) | D-D | Stricture | CCS | 30 | 107 | – | – | Failure | ||
| 18 | 33 | M | Liver failure (HAV) | D-D | Stricture | CCS | N/A | 5 | 33 | 26.7 | Success | ||
| 19 | 61 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 4 | 14 | 25.4 | Success | ||
| 20 | 54 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 9 | 181 | 7.3 | Success | ||
| 21 | 52 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 1 | 153 | N/A | Success | ||
| 22 | 51 | M | LC (HBV) | D-D | Stricture | CCS | N/A | 5 | – | – | Failure | ||
| 2014 | Uemura et al. [ | 23 | 49 | F | LC (HCV) | D-D | Obstruction | CCS | 11 | 11 | 24 | 13 | Success |
| 2016 | Ersoz et al. [ | 24 | 37 | M | LC (HBV) | D-D | Dehiscence | CCS | 15 | 12 | 13 | N/A | Success |
| 25 | 54 | F | LC (HBV, HDV) | D-D | Dehiscence | CCS | 10 | 84 | 14 | N/A | Success | ||
| 26 | 53 | F | LC (HCV) | D-D | Dehiscence | CCS | 10 | 14 | 42 | N/A | Success | ||
| 27 | 63 | M | LC (HBV) | D-D | Dehiscence | CCS | 5 | 7 | 18 | N/A | Success | ||
| 28 | 68 | F | LC (HBV) | D-D | Dehiscence | CCS | 10 | 6 | 22 | N/A | Success | ||
| 29 | 54 | M | LC (HBV) | D-D | Dehiscence | CCS | 15 | 7 | 13 | N/A | Success | ||
| 2017 | Saito et al. [ | 30 | 54 | F | LC (PSC) | R-Y | Strangulated ileus | CDS | 27 | 60 | 25 | 44 | Success |
| 2017 | Parlak et al. [ | 31 | 68 | F | LC (HCV) | D-D | Obstruction | CCS | 2.5 | 14 | 7 | 36 | Success |
| 32 | 52 | M | LC (HBV) | D-D | Obstruction | CCS | 3 | 22 | 10 | N/A | Success | ||
| 33 | 55 | M | LC (HBV) | D-D | Obstruction | CCS | 4 | 16 | 2 | 36 | Success | ||
| 34 | 58 | M | LC (Cryptogenic) | D-D | Obstruction | CCS | 6 | 34 | 14 | 48 | Success | ||
| 35 | 38 | F | LC (HBV) | D-D | Obstruction | CCS | 3 | 38 | 12 | 48 | Success | ||
| 36 | 63 | F | LC (HCV) | D-D | Obstruction | CCS | 3 | 13 | 2 | 44 | Success | ||
| 37 | 52 | M | LC (HBV) | D-D | Obstruction | CCS | 4 | 60 | 10 | N/A | Success | ||
| 38 | 54 | M | LC (HBV) | D-D | Obstruction | CCS | 5 | 15 | – | – | Failure | ||
| 39 | 62 | M | LC (Cryptogenic) | D-D | Obstruction | CCS | 5 | 5 | – | – | Failure | ||
| 2018 | Kubo | 40 | 55 | F | LC (PSC) | R-Y | Dehiscence | CJS | 10 | 12 | 21 | 48 | Success |
| Dehiscence | CJS | 10 | 14 | 47 | 76 | Success | |||||||
| Mean | 51.6 | s | 8.9 | 22.6 | 35.5 | 37.6 | 36/40(90.0%) |
FH fulminant hepatitis, LC liver cirrhosis, HAV hepatitis type A virus, HBV hepatitis type B virus, HCV hepatitis type C virus, PSC primary sclerosing cholangitis, D-D duct-to-duct anastomosis, R-Y Roux en Y anastomosis, CCS choledochocholedochostomy, CDS choledochoduodenostomy, CJS choledochojejunostomy, N/A not addressed